Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions

被引:36
|
作者
Ferrara, Giovanni [1 ,2 ,3 ]
Luppi, Fabrizio [4 ]
Birring, Surinder S. [5 ]
Cerri, Stefania [4 ]
Caminati, Antonella [6 ]
Skold, Magnus [1 ,2 ,3 ]
Kreuter, Michael [7 ,8 ]
机构
[1] Karolinska Inst, Sect Resp Med, Dept Med Solna, Stockholm, Sweden
[2] Karolinska Inst, Ctr Mol Med, Stockholm, Sweden
[3] Karolinska Univ Hosp Solna, Div Resp Med & Allergy, Stockholm, Sweden
[4] Univ Hosp Modena, Ctr Rare Lung Dis, Modena, Italy
[5] Kings Coll London, Div Asthma Allergy & Lung Biol, London, England
[6] San Giuseppe Hosp Multimed, Sect Resp Med, Milan, Italy
[7] Heidelberg Univ, Heidelberg, Germany
[8] Heidelberg Univ, Div Resp Med, Ctr Interstitial & Rare Lung Dis, Heidelberg, Germany
来源
EUROPEAN RESPIRATORY REVIEW | 2018年 / 27卷 / 147期
关键词
INTERSTITIAL LUNG-DISEASE; QUALITY-OF-LIFE; HEALTH-STATUS; CONTROLLED-TRIAL; CLINICAL-TRIALS; ANTACID THERAPY; PALLIATIVE CARE; CHRONIC COUGH; COPD PATIENTS; K-BILD;
D O I
10.1183/16000617.0076-2017
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Best supportive care (BSC) is generally defined as all the interventions and the multiprofessional approach aimed to improve and optimise quality of life (QoL) in patients affected by progressive diseases. In this sense, it excludes and might be complementary to other interventions directly targeting the disease. BSC improves survival in patients with different types of cancer. Patients with idiopathic pulmonary fibrosis (IPF) experience a vast range of symptoms during the natural history of the disease and might have a beneficial effect of BSC interventions. This review highlights the current evidence on interventions targeting QoL and gaps for the clinical assessment of BSC in the treatment of IPF patients. Very few interventions to improve QoL or improve symptom control are currently supported by well-designed studies. Sound methodology is paramount in evaluating BSC in IPF, as well as the use of validated tools to measure QoL and symptom control in this specific group of patients.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Idiopathic pulmonary fibrosis: current and future directions
    Soo, E.
    Adamali, H.
    Edey, A. J.
    CLINICAL RADIOLOGY, 2017, 72 (05) : 343 - 355
  • [2] Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis
    Loomis-King, Hillary
    Flaherty, Kevin R.
    Moore, Bethany B.
    CURRENT OPINION IN PHARMACOLOGY, 2013, 13 (03) : 377 - 385
  • [3] Future Directions in Idiopathic Pulmonary Fibrosis Research
    Blackwell, Timothy S.
    Tager, Andrew M.
    Borok, Zea
    Moore, Bethany B.
    Schwartz, David A.
    Anstrom, Kevin J.
    Bar-Joseph, Ziv
    Bitterman, Peter
    Blackburn, Michael R.
    Bradford, William
    Brown, Kevin K.
    Chapman, Harold A.
    Collard, Harold R.
    Cosgrove, Gregory P.
    Deterding, Robin
    Doyle, Ramona
    Flaherty, Kevin R.
    Garcia, Christine Kim
    Hagood, James S.
    Henke, Craig A.
    Herzog, Erica
    Hogaboam, Cory M.
    Horowitz, Jeffrey C.
    King, Talmadge E., Jr.
    Loyd, James E.
    Lawson, William E.
    Marsh, Clay B.
    Noble, Paul W.
    Noth, Imre
    Sheppard, Dean
    Olsson, Julie
    Ortiz, Luis A.
    O'Riordan, Thomas G.
    Oury, Tim D.
    Raghu, Ganesh
    Roman, Jesse
    Sime, Patricia J.
    Sisson, Thomas H.
    Tschumperlin, Daniel
    Violette, Shelia M.
    Weaver, Timothy E.
    Wells, Rebecca G.
    White, Eric S.
    Kaminski, Naftali
    Martinez, Fernando J.
    Wynn, Thomas A.
    Thannickal, Victor J.
    Eu, Jerry P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189 (02) : 214 - 222
  • [4] Predicting life expectancy for pirfenidone and best supportive care (BSC) in idiopathic pulmonary fibrosis (IPF)
    Fisher, Mark
    Maher, Toby M.
    Nathan, Steven D.
    Hill, Christian
    Marshall, Jade
    Dejonckheere, Fred
    Thuresson, Per-Olof
    Mathew, Nitya
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [5] Current and Future Therapies for Idiopathic Pulmonary Fibrosis
    Spagnolo P.
    Bonella F.
    Vasakova M.
    Kreuter M.
    Maher T.M.
    Pulmonary Therapy, 2015, 1 (1) : 1 - 18
  • [6] Idiopathic pulmonary fibrosis: Current and future treatment
    Glass, Daniel S.
    Grossfeld, David
    Renna, Heather A.
    Agarwala, Priya
    Spiegler, Peter
    DeLeon, Joshua
    Reiss, Allison B.
    CLINICAL RESPIRATORY JOURNAL, 2022, 16 (02): : 84 - 96
  • [7] Current and Future Idiopathic Pulmonary Fibrosis Therapy
    Richeldi, Luca
    Baldi, Fabiana
    Pasciuto, Giuliana
    Macagno, Francesco
    Panico, Loredana
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2019, 357 (05): : 370 - 373
  • [8] Current and future treatment for idiopathic pulmonary fibrosis
    Choi, Won-Il
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2021, 64 (04): : 256 - 263
  • [9] A supportive care decision aid tool for idiopathic pulmonary fibrosis
    Sharp, Charles
    Edwards, Adrienne
    Lamb, Heather
    Alam, Sorayya
    Jordan, Nikki
    Gunary, Rachel
    Meek, Patricia
    Millar, Ann
    Kendall, Clare
    Adamali, Huzaifa
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [10] Idiopathic pulmonary fibrosis and lung cancer: future directions and challenges
    Abu Qubo, Ahmad
    Numan, Jamil
    Snijder, Juan
    Padilla, Maria
    Austin, John H. M.
    Capaccione, Kathleen M.
    Pernia, Monica
    Bustamante, Jean
    O'Connor, Timothy
    Salvatore, Mary M.
    BREATHE, 2022, 18 (04)